HC Wainwright Has Optimistic Outlook of XOMA FY2025 Earnings

XOMA Co. (NASDAQ:XOMA) – HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of XOMA in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company will post earnings per share of $0.17 for the year, up from their previous forecast of $0.15. HC Wainwright currently has a “Buy” rating and a $117.00 target price on the stock. The consensus estimate for XOMA’s current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for XOMA’s FY2026 earnings at $0.64 EPS.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). XOMA had a negative return on equity of 24.57% and a negative net margin of 151.34%. The company had revenue of $11.09 million during the quarter, compared to analysts’ expectations of $8.37 million.

Separately, StockNews.com raised shares of XOMA from a “sell” rating to a “hold” rating in a research note on Wednesday, August 14th.

XOMA Stock Performance

XOMA stock opened at $31.26 on Monday. XOMA has a fifty-two week low of $14.33 and a fifty-two week high of $33.78. The firm’s 50 day simple moving average is $28.57 and its 200-day simple moving average is $26.82. The company has a debt-to-equity ratio of 1.15, a current ratio of 8.71 and a quick ratio of 8.71. The company has a market cap of $365.87 million, a P/E ratio of -8.98 and a beta of 0.90.

Institutional Trading of XOMA

Hedge funds have recently made changes to their positions in the stock. Ellsworth Advisors LLC acquired a new position in XOMA in the 3rd quarter valued at approximately $516,000. Rhumbline Advisers grew its holdings in shares of XOMA by 16.0% during the 2nd quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after acquiring an additional 1,334 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 1,266 shares during the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in XOMA during the first quarter valued at $212,000. Finally, Bank of New York Mellon Corp grew its stake in XOMA by 3.2% in the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares in the last quarter. 95.92% of the stock is owned by hedge funds and other institutional investors.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.